58972-21-7

Basic information

• Product Name: Methyl 5-benzoylfuran-2-carboxylate
• Synonyms: METHYL-5-BENZOYL-2-FURANCARBOXYLATE;METHYL 5-BENZOYL-FURAN-2-CARBOXYLATE;5-Methoxycarbonyl-2-furyl phenyl ketone;5-BENZOYL-FURAN-2-CARBOXYLIC ACID METHYL ESTER;2-Furancarboxylic acid, 5-benzoyl-, methyl ester
• CAS NO: 58972-21-7
• Molecular Formula: C₁₃H₁₀O₄
• Molecular Weight: 230.22
• Mol File: 58972-21-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 78-79 °C
• Boiling Point: 368.611 °C at 760 mmHg
• Flash Point: 176.73 °C
• Appearance: /
• Density: 1.223 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 5-benzoylfuran-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-benzoylfuran-2-carboxylate(58972-21-7)
• EPA Substance Registry System: Methyl 5-benzoylfuran-2-carboxylate(58972-21-7)

Safety Data

• Hazardous Substances Data: 58972-21-7(Hazardous Substances Data)

Usage

General Description

Methyl 5-benzoylfuran-2-carboxylate is a chemical compound with the molecular formula C13H10O4. It is a yellow crystalline solid with a slightly sweet odor, commonly used as a flavoring agent in the food industry. Methyl 5-benzoylfuran-2-carboxylate is also used in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is known for its aromatic properties, and its structure consists of a furan ring with a benzoyl group attached to the 5-position and a methyl ester group attached to the 2-position. Methyl 5-benzoylfuran-2-carboxylate is considered to be relatively stable under normal conditions and is generally handled and stored as a solid or in solution form.

InChI:InChI=1/C13H10O4/c1-16-13(15)11-8-7-10(17-11)12(14)9-5-3-2-4-6-9/h2-8H,1H3

Upstream product

• 2527-98-2 methyl 5-bromo-2-furoate 
• 611-73-4 Benzoylformic acid 
• 67-56-1 methanol 
• 2689-59-0 (furan-2-yl)(phenyl)methanone 
• 67-66-3 chloroform 
• 611-13-2 2-furoic acid methyl ester 
• 93-97-0 benzoic acid anhydride 
• 98-88-4 benzoyl chloride 
• 98-07-7 Benzotrichlorid 
• 2527-99-3 methyl 5-bromo-2-furoate 
• 201230-82-2 carbon monoxide 
• 98-80-6 phenylboronic acid 

Downstream Products

• 154232-83-4 5-(hydroxy-phenyl-methyl)-furan-2-carboxylic acid methyl ester 
• 35897-51-9 5-benzoyl-furan-2-carboxylic acid 
• 1917-16-4 5-benzyl-furan-2-carboxylic acid 

Relevant articles and documents

N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties

Urea transporters (UTs) have been identified as new targets for diuretics. Functional deletion of UTs led to urea-selective urinary concentrating defects with relative salt sparing. In our previous study, a UT inhibitor with a diarylamide scaffold, which is denoted as 11a, was demonstrated as the first orally available UT inhibitor. However, the oral bioavailability of 11a was only 4.38%, which obstructed its clinical application. In this work, by replacing the nitro group of 11a with an acetyl group, 25a was obtained. Compared with 11a, 25a showed a 10 times stronger inhibitory effect on UT-B (0.14 μM vs. 1.41 μM in rats, and 0.48 μM vs. 5.82 μM in mice) and a much higher inhibition rate on UT-A1. Moreover, the metabolic stability both in vitro and in vivo and the drug-like properties (permeability and solubility) of 25a were obviously improved compared with those of 11a. Moreover, the bioavailability of 25a was 15.18%, which was 3 times higher than that of 11a, thereby resulting in significant enhancement of the diuretic activities in rats and mice. 25a showed excellent potential for development as a promising clinical diuretic candidate for targeting UTs to treat diseases that require long-term usage of diuretics, such as hyponatremia.

FIVE-MEMBERED HETEROCYCLIC DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a five-membered heterocyclic compound having an analgesic effect and a pharmaceutical composition comprising a derivative of the five-membered heterocyclic compound. More specifically, the present invention relates to a me

EP2 RECEPTOR AGONISTS

A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.